Article
Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C.
Annals of hepatology - 1 Jan 2000
Forns Xavier, Didier Samuel, Mutimer David, Fagiuoli Stefano, Navasa Miquel, Agarwal Kosh, Berenguer Marina, Colombo Massimo, Herzer Kerstin, Nevens Frederik, Daems Bjorn, Janssen Katrien, Ouwerkerk-Mahadevan Sivi, Kimko Holly, Lathouwers Erkki, Witek James, Van Solingen-Ristea Rodica
Abstract excerpt
UNLABELLED: Background and rationale. The REPLACE study (NCT01571583) investigated telaprevir-based triple therapy in patients who have recurrent genotype 1 hepatitis C virus (HCV) infection following liver transplantation and are on a stable immunosuppressant regimen of tacrolimus or cyclosporin A. Patients received telaprevir 750 mg 8-hourly with pegylated interferon 180 ?g weekly and ribavirin 600 mg daily,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.